Translate 
Abstract
Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide. The rising prevalence of CVD is primarily driven by several risk factors, including dyslipidemia, atherosclerosis, diabetes, and obesity. Many current studies are focused on unraveling the underlying pathophysiological mechanisms that govern these risk factors, with the main goal of identifying novel biomarkers and therapeutic targets to prevent the onset of CVD in the population. In recent decades, genome-wide association studies (GWASs) have linked the 8q24 locus containing the TRIB1 (Tribbles homolog 1) gene to various cardiometabolic traits in humans, such as plasma triglycerides, LDL cholesterol, HDL cholesterol, total cholesterol, adiponectin, and glycated hemoglobin levels. Emerging research has investigated the role of Trib1 in regulating plasma lipid levels, inflammation, and insulin signaling, opening new avenues for the potential therapeutic role of Trib1 in CVD risk assessment. Accordingly, this review aims to explore the crucial role of Trib1 as a therapeutic biomarker in CVDs, with a focus on its association with lipid metabolism, atherosclerosis, obesity, and diabetes, analyzing in vitro and in vivo studies and offering insights into its underlying molecular mechanisms.
Published Version
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
